Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population

References

• FerlayJSoerjomataramIErvikMGLOBOCAN 2012 v10, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11LyonInternational Agency for Research on Cancer2013 Available from: http://globocan.iarc.fr
   Google Scholar
• SoerjomataramILortet-TieulentJParkinDMGlobal burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regionsLancet20123801840185023079588
   PubMed Web of Science ®Google Scholar
• JemalACenterMMDeSantisCWardEMGlobal patterns of cancer incidence and mortality rates and trendsCancer Epidemiol Biomarkers Prev2010191893190720647400
   PubMed Web of Science ®Google Scholar
• PatelJDKrilovLAdamsSClinical cancer advances 2013: annual report on progress against cancer from the American society of clinical oncologyJ Clin Oncol20143212916024327669
   PubMed Web of Science ®Google Scholar
• KantarjianHMFojoTMathisenMZwellingLACancer drugs in the United States: Justum Pretium – the just priceJ Clin Oncol2013313600360423650428
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceGuide to the Methods of Technology AppraisalLondonNational Institute for Health and Clinical Excellence (NICE)2008
   Google Scholar
• NeumannPJSandbergEABellCMStonePWChapmanRHAre pharmaceuticals cost-effective? A review of the evidence?Health Aff (Millwood)2000199210910718025
   PubMed Web of Science ®Google Scholar
• SacristánJAOlivaJDel LlanoJPrietoLPintoJLWhat is an efficient health technology in Spain?Gac Sanit20021633434312113733
   PubMedGoogle Scholar
• KingJTJrTsevatJLaveJRRobertsMSWillingness to pay for a quality-adjusted life year: implications for societal health care resource allocationMed Decis Making20052566767716282217
   PubMed Web of Science ®Google Scholar
• EllisLMBernsteinDSVoestEEAmerican society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomesJ Clin Oncol2014321277128024638016
   PubMed Web of Science ®Google Scholar
• SlevinMLStubbsLPlantHJAttitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general publicBMJ1990300145814602379006
   PubMed Web of Science ®Google Scholar
• BerrySRBellCMUbelPAContinental divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugsJ Clin Oncol2010284149415320697077
   PubMed Web of Science ®Google Scholar
• NeumannPJPalmerJANadlerEFangCUbelPCancer therapy costs influence treatment: a national survey of oncologistsHealth Aff (Millwood)20102919620220048377
   PubMed Web of Science ®Google Scholar
• GreenbergDHammermanAVinkerSShaniAYermiahuYNeumannPJOncologists’ and family physicians’ views on value for money of cancer and congestive heart failure careIsr J Health Policy Res201324424245811
   PubMed Web of Science ®Google Scholar
• NadlerEEckertBNeumannPDo oncologists believe new cancer drugs offer good value?Oncologist200611909516476830
   PubMed Web of Science ®Google Scholar
• KozminskiMANeumannPJNadlerESJankovicAUbelPAHow long and how well: oncologists’ attitudes toward the relative value of life-prolonging v quality of life-enhancing treatmentsMed Decis Making20113138038521088130
   PubMed Web of Science ®Google Scholar
• UbelPABerrySRNadlerEIn a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survivalHealth Aff (Millwood)20123170971722492887
   PubMed Web of Science ®Google Scholar
• GreenbergDHammermanAVinkerSShaniAYermiahuYNeumannPJWhich is more valuable, longer survival or better quality of life? Israeli oncologists’ and family physicians’ attitudes toward the relative value of new cancer and congestive heart failure interventionsValue Health20131684284723947979
   PubMed Web of Science ®Google Scholar
• BraithwaiteRSMeltzerDOKingJTJrLeslieDRobertsMSWhat does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?Med Care20084634935618362813
   PubMed Web of Science ®Google Scholar
• TowseAShould NICE’s threshold range for cost per QALY be raised? YesBMJ2009338b18119171561
   PubMed Web of Science ®Google Scholar
• RafteryJShould NICE’s threshold range for cost per QALY be raised? NoBMJ2009338b18519171562
   PubMed Web of Science ®Google Scholar
• ClaxtonKMartinSSoaresMMethods for the Estimation of the NICE Cost Effectiveness ThresholdYorkCentre for Health Economics; University of York201381
   Google Scholar
• NeumannPJCohenJTWeinsteinMCUpdating cost-effectiveness – the curious resilience of the $50,000-per-QALY thresholdN Engl J Med201437179679725162885
   PubMed Web of Science ®Google Scholar
• GreenbergDEarleCFangCHEldar-LissaiANeumannPJWhen is cancer care cost-effective? A systematic overview of cost-utility analyses in oncologyJ Natl Cancer Inst2012102828820056956
   PubMedGoogle Scholar
• Camps-HerreroCPaz-AresLCodesMSocial value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologistsClin Transl Oncol20141691492024924625
   PubMed Web of Science ®Google Scholar
• SacristánJAPatient-centered medicine and patient-oriented research: improving health outcomes for individual patientsBMC Med Inform Decis Mak201313623294526
   PubMed Web of Science ®Google Scholar
• BaschEAbernethyAPMullinsCDRecommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncologyJ Clin Oncol2012304249425523071244
   PubMed Web of Science ®Google Scholar
• RockeDJBeumerHWTaylorDHThomasSPuscasLLeeWTPhysician and patient and caregiver health attitudes and their effect on medicare resource allocation for patients with advanced cancerJAMA Otolaryngol Head Neck Surg2014140649750324763550
   PubMed Web of Science ®Google Scholar
• RafteryJPPaying for costly pharmaceuticals: regulation of new drugs in Australia, England and New ZealandMed J Aust2008188262818205559
   PubMed Web of Science ®Google Scholar
• RocchiAMenonDVermaSMillerEThe role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyondValue Health20081177178318179658
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceAppraising Life-Extending, End of Life TreatmentsLondonNICE2009
   Google Scholar
• MoïsePFasslerPEstimating NICE’s cost-effectiveness threshold for end-of-life cancer treatments [abstract]Value Health201114A173
   Web of Science ®Google Scholar
• LakdawallaDNJenaABDoctorJNCareful use of science to advance the debate on the UK cancer drugs fundJAMA2014311252624381964
   PubMed Web of Science ®Google Scholar
• MarshallBCardonPPoddarADoes sample size matter in qualitative research?: a review of qualitative interviews in is researchJ Comput Inform Syst20135411122
   Web of Science ®Google Scholar